Our Programs

Our pipeline includes four clinical-stage drug candidates targeting different mechanisms critical to overcoming cancer progression and drug resistance:

• ME-401, an oral PI3K delta inhibitor;
• Voruciclib, an oral CDK inhibitor; and
• ME-344, a mitochondrial inhibitor targeting the OXPHOS complex.
• Pracinostat, an oral HDAC inhibitor;

Our portfolio is built around drug candidates with validated targets and is designed to develop medicines that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other medicines.

ME-401 Oral P13K Delta Inhibitor
INDICATION	COMBINATION	CLINICAL PROOF OF CONCEPT	MARKETING APPROVAL STUDY	COMMERCIAL RIGHTS
Follicular Lymphoma Relapsed/refractory	Monotherapy	Phase 2 Accelerated Approval Trial 1		Excluding Japan Japan
B-Cell Malignancies Relapsed/refractory	Monotherapy Rituxan® (rituximab) Zanubrutinib2	60% 60% clinical collaboration

Voruciclib CDK Inhibitor
INDICATION	COMBINATION	CLINICAL PROOF OF CONCEPT	MARKETING APPROVAL STUDY	COMMERCIAL RIGHTS
B-Cell Malignancies & AML Relapsed/refractory	Venclexta® (venetoclax)3	60%

ME-344 Mitochondrial Inhibitor
INDICATION	COMBINATION	CLINICAL PROOF OF CONCEPT	MARKETING APPROVAL STUDY	COMMERCIAL RIGHTS
HER2-Breast Cancer Treatment-naive, early stage	Avastin® (bevacizumab)4	60%

Pracinostat HDAC Inhibitor
INDICATION	COMBINATION	CLINICAL PROOF OF CONCEPT	MARKETING APPROVAL STUDY	COMMERCIAL RIGHTS
Acute Myeloid Leukemia Treatment-naive	Vidaza® (azacitidine)	Phase 3 Pivotal Trial
Myelodysplastic Syndrome Treatment-naive	Vidaza® (azacitidine)	60%

¹ Phase 2 study to support an accelerated approval marketing application with FDA
² Study arm initiated under clinical collaboration with BeiGene, Ltd.
³ Evaluation in combination with venetoclax is subject to FDA approval
⁴ Investigator-initiated trial